Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency, together, drive in vivo efficacy by Lundy, M, Ebetino, F, Fei, L, Xia, Z, Pozzi, M, Trokhan, D, Phipps, R, Dunford, J, Triffitt, J, Russell, R